Literature DB >> 24849726

Suppression of oxidative stress and 5-lipoxygenase activation by edaravone improves depressive-like behavior after concussion.

Youichirou Higashi1, Michihiro Hoshijima, Toshio Yawata, Atsuya Nobumoto, Masayuki Tsuda, Takahiro Shimizu, Motoaki Saito, Tetuya Ueba.   

Abstract

Brain concussions are a serious public concern and are associated with neuropsychiatric disorders, such as depression. Patients with concussion who suffer from depression often experience distress. Nevertheless, few pre-clinical studies have examined concussion-induced depression, and there is little information regarding its pharmacological management. Edaravone, a free radical scavenger, can exert neuroprotective effects in several animal models of neurological disorders. However, the effectiveness of edaravone in animal models of concussion-induced depression remains unclear. In this study, we examined whether edaravone could prevent concussion-induced depression. Mice were subjected to a weight-drop injury and intravenously administered edaravone (3.0 mg/kg) or vehicle immediately after impact. Serial magnetic resonance imaging showed no abnormalities of the cerebrum on diffusion T1- and T2-weighted images. We found that edaravone suppressed concussion-induced depressive-like behavior in the forced swim test, which was accompanied by inhibition of increased hippocampal and cortical oxidative stress (OS) and suppression of 5-lipoxygenase (5-LOX) translocation to the nuclear envelope in hippocampal astrocytes. Hippocampal OS in concussed mice was also prevented by the nicotinamide adenine dinucleotide phosphate oxidase inhibitor, apocynin, and administration of BWB70C, a 5-LOX inhibitor, immediately and 24 h after injury prevented depressive-like behaviors in concussed mice. Further, antidepressant effects of edaravone were observed in mice receiving 1.0 or 3.0 mg/kg of edaravone immediately after impact, but not at a lower dose of 0.1 mg/kg. This antidepressant effect persisted up to 1 h after impact, whereas edaravone treatment at 3 h after impact had no effect on concussion-induced depressive-like behavior. These results suggest that edaravone protects against concussion-induced depression, and this protection is mediated by suppression of OS and 5-LOX translocation.

Entities:  

Keywords:  5-lipoxygenase; concussion; depression; edaravone

Mesh:

Substances:

Year:  2014        PMID: 24849726      PMCID: PMC4180298          DOI: 10.1089/neu.2014.3331

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  58 in total

1.  Mild traumatic brain injury induces persistent cognitive deficits and behavioral disturbances in mice.

Authors:  A Milman; A Rosenberg; R Weizman; C G Pick
Journal:  J Neurotrauma       Date:  2005-09       Impact factor: 5.269

Review 2.  Role of neurotrophic factors in depression.

Authors:  Eero Castrén; Vootele Võikar; Tomi Rantamäki
Journal:  Curr Opin Pharmacol       Date:  2006-10-17       Impact factor: 5.547

3.  Metabolism of 5-hydroxy-6,8,11,14-eicosatetraenoic acid by human endothelial cells.

Authors:  Karl-Rudolf Erlemann; Chantal Cossette; Sylvie Gravel; Panagiota B Stamatiou; Gue-Jae Lee; Joshua Rokach; William S Powell
Journal:  Biochem Biophys Res Commun       Date:  2006-09-12       Impact factor: 3.575

4.  Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma.

Authors:  Lei Zhang; Wei-Ping Zhang; Hua Hu; Meng-Ling Wang; Wen-Wen Sheng; Hong-Tian Yao; Wei Ding; Zhong Chen; Er-Qing Wei
Journal:  Neuropathology       Date:  2006-04       Impact factor: 1.906

5.  The radical scavenger edaravone prevents oxidative neurotoxicity induced by peroxynitrite and activated microglia.

Authors:  Masahiro Banno; Tetsuya Mizuno; Hideki Kato; Guiqin Zhang; Jun Kawanokuchi; Jinyan Wang; Reiko Kuno; Shijie Jin; Hideyuki Takeuchi; Akio Suzumura
Journal:  Neuropharmacology       Date:  2004-12-24       Impact factor: 5.250

Review 6.  5-Lipoxygenase: regulation of expression and enzyme activity.

Authors:  Olof Rådmark; Oliver Werz; Dieter Steinhilber; Bengt Samuelsson
Journal:  Trends Biochem Sci       Date:  2007-06-18       Impact factor: 13.807

7.  Time course of post-traumatic mitochondrial oxidative damage and dysfunction in a mouse model of focal traumatic brain injury: implications for neuroprotective therapy.

Authors:  Indrapal N Singh; Patrick G Sullivan; Ying Deng; Lamin H Mbye; Edward D Hall
Journal:  J Cereb Blood Flow Metab       Date:  2006-03-15       Impact factor: 6.200

8.  Effects of MK-886, a 5-lipoxygenase activating protein (FLAP) inhibitor, and 5-lipoxygenase deficiency on the forced swimming behavior of mice.

Authors:  Tolga Uz; Nikola Dimitrijevic; Marta Imbesi; Hari Manev; Radmila Manev
Journal:  Neurosci Lett       Date:  2008-03-21       Impact factor: 3.046

9.  The novel antioxidant edaravone: from bench to bedside.

Authors:  Toshiaki Watanabe; Munenori Tahara; Satoru Todo
Journal:  Cardiovasc Ther       Date:  2008       Impact factor: 3.023

10.  Corticosterone as a marker of susceptibility to oxidative/nitrosative cerebral damage after stress exposure in rats.

Authors:  B G Pérez-Nievas; B García-Bueno; J R Caso; L Menchén; J C Leza
Journal:  Psychoneuroendocrinology       Date:  2007-06-11       Impact factor: 4.905

View more
  6 in total

1.  A combination antioxidant therapy to inhibit NOX2 and activate Nrf2 decreases secondary brain damage and improves functional recovery after traumatic brain injury.

Authors:  Raghavendar Chandran; TaeHee Kim; Suresh L Mehta; Eshwar Udho; Vishal Chanana; Pelin Cengiz; HwuiWon Kim; Chanul Kim; Raghu Vemuganti
Journal:  J Cereb Blood Flow Metab       Date:  2017-10-30       Impact factor: 6.200

Review 2.  Elucidating opportunities and pitfalls in the treatment of experimental traumatic brain injury to optimize and facilitate clinical translation.

Authors:  Patricia B de la Tremblaye; Darik A O'Neil; Megan J LaPorte; Jeffrey P Cheng; Joshua A Beitchman; Theresa Currier Thomas; Corina O Bondi; Anthony E Kline
Journal:  Neurosci Biobehav Rev       Date:  2017-05-30       Impact factor: 8.989

3.  Combined treatment with GSNO and CAPE accelerates functional recovery via additive antioxidant activities in a mouse model of TBI.

Authors:  Mushfiquddin Khan; Anandakumar Shunmugavel; Tajinder S Dhammu; Hamza Khan; Inderjit Singh; Avtar K Singh
Journal:  J Neurosci Res       Date:  2018-07-19       Impact factor: 4.164

4.  Absence of ALOX5 gene prevents stress-induced memory deficits, synaptic dysfunction and tauopathy in a mouse model of Alzheimer's disease.

Authors:  Yash B Joshi; Phillip F Giannopoulos; Jin Chu; Margaret Sperow; Lynn G Kirby; Mary E Abood; Domenico Praticò
Journal:  Hum Mol Genet       Date:  2014-08-13       Impact factor: 6.150

Review 5.  Traumatic brain injury and the development of parkinsonism: Understanding pathophysiology, animal models, and therapeutic targets.

Authors:  Smrithi Padmakumar; Praveen Kulkarni; Craig F Ferris; Benjamin S Bleier; Mansoor M Amiji
Journal:  Biomed Pharmacother       Date:  2022-03-12       Impact factor: 7.419

6.  Edaravone attenuates neuronal apoptosis in hippocampus of rat traumatic brain injury model via activation of BDNF/TrkB signaling pathway.

Authors:  Yuexia Ding; Wei Zhu; Wei Kong; Tuo Li; Peng Zou; Hongguang Chen
Journal:  Arch Med Sci       Date:  2019-11-18       Impact factor: 3.318

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.